• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Is prasugrel superior to clopidogrel for patients with acute coronary syndromes undergoing PCI?

作者信息

Bhatt Deepak L

机构信息

Department of Cardiovascular Medicine, Cleveland Clinic, Desk F25, 9500 Euclid Avenue, Cleveland, OH 44195, USA.

出版信息

Nat Clin Pract Cardiovasc Med. 2008 May;5(5):252-3. doi: 10.1038/ncpcardio1164. Epub 2008 Mar 25.

DOI:10.1038/ncpcardio1164
PMID:18364708
Abstract
摘要

相似文献

1
Is prasugrel superior to clopidogrel for patients with acute coronary syndromes undergoing PCI?对于接受经皮冠状动脉介入治疗（PCI）的急性冠状动脉综合征患者，普拉格雷是否优于氯吡格雷？
Nat Clin Pract Cardiovasc Med. 2008 May;5(5):252-3. doi: 10.1038/ncpcardio1164. Epub 2008 Mar 25.
2
Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.普拉格雷与氯吡格雷对未植入支架行经皮冠状动脉介入治疗的急性冠脉综合征患者预后的影响：一项通过优化血小板抑制作用评估普拉格雷改善治疗转归的试验（TRITON）-心肌梗死溶栓试验（TIMI）38亚组研究
Am Heart J. 2009 Sep;158(3):e21-6. doi: 10.1016/j.ahj.2009.06.021.
3
Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes.新型P2Y(12)受体拮抗剂普拉格雷在急性冠脉综合征治疗中的作用。
Am J Cardiovasc Drugs. 2009;9(4):213-29. doi: 10.2165/1131209-000000000-00000.
4
Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.氯吡格雷用于冠心病患者的获益与风险：来自随机研究和注册登记研究的证据
Clin Ther. 2008;30 Pt 2:2191-202. doi: 10.1016/j.clinthera.2008.12.001.
5
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.普拉格雷联合或不联合糖蛋白IIb/IIIa抑制剂在接受经皮介入治疗的急性冠脉综合征患者中的疗效与安全性：TRITON-TIMI 38（通过优化普拉格雷血小板抑制评估治疗转归改善情况-心肌梗死溶栓试验38）分析
J Am Coll Cardiol. 2009 Aug 18;54(8):678-85. doi: 10.1016/j.jacc.2009.05.025.
6
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.普拉格雷对接受经皮冠状动脉介入治疗的急性冠脉综合征患者的早期和晚期获益：TRITON-TIMI 38（通过普拉格雷优化血小板抑制评估治疗转归改善的试验-心肌梗死溶栓38）分析
J Am Coll Cardiol. 2008 May 27;51(21):2028-33. doi: 10.1016/j.jacc.2008.04.002.
7
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.替格瑞洛与氯吡格雷在TRITON-TIMI 38试验中对血小板抑制作用的药效学评估。
Eur Heart J. 2009 Jul;30(14):1753-63. doi: 10.1093/eurheartj/ehp159. Epub 2009 May 12.
8
The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.普拉格雷在急性冠状动脉综合征患者缺血事件二级预防中的潜在作用。
Postgrad Med. 2009 Jan;121(1):59-72. doi: 10.3810/pgm.2009.01.1955.
9
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.普拉格雷：新药。血管成形术和支架置入术后：继续使用阿司匹林+氯吡格雷。
Prescrire Int. 2009 Oct;18(103):193-5.
10
Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials.普拉格雷与氯吡格雷在急性冠脉综合征患者中的疗效及安全性比较：TRITON-TIMI 38试验结果
Expert Rev Cardiovasc Ther. 2009 Jan;7(1):17-23. doi: 10.1586/14779072.7.1.17.

引用本文的文献

1
Application of personalized medicine to chronic disease: a feasibility assessment.个性化医学在慢性病中的应用：可行性评估。
Clin Transl Med. 2013 Dec 18;2(1):16. doi: 10.1186/2001-1326-2-16.
2
The evolution of antiplatelet therapy in cardiovascular disease.抗血小板治疗在心血管疾病中的演变。
Nat Rev Cardiol. 2011 Jul 12;8(10):547-59. doi: 10.1038/nrcardio.2011.96.
3
Antiplatelet therapy: Ticagrelor in ACS-what does PLATO teach us?抗血小板治疗：替格瑞洛在急性冠脉综合征中的应用——PLATO研究给我们带来了什么启示？
Nat Rev Cardiol. 2009 Dec;6(12):737-8. doi: 10.1038/nrcardio.2009.192.